Mirnas and HIV: Unforeseen Determinants Of Host-Pathogen Interaction

Immunological Reviews

Volumn 254, Issue 1, 2013, Pages 265-280

  Swaminathan, Sanjay ^a   Murray, Daniel D ^b,c   Kelleher, Anthony D ^b,c  

^a SAIC FREDERICK INC   (United States)

^b St Vincent's Centre for Applied Medical Research   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Biomarkers; CD4+ T cell; Cytokines; HIV 1; MiRNA; Monocytes

Indexed keywords

ANTIRETROVIRUS AGENT; HLA C ANTIGEN; MICRORNA; MICRORNA 125B; MICRORNA 29A; MICRORNA 29B; SHORT HAIRPIN RNA;

ALLELE; ANTIGEN EXPRESSION; ANTIVIRAL THERAPY; ARTICLE; BIOGENESIS; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; HLA SYSTEM; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOMODULATION; INFECTION CONTROL; MACROPHAGE; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; BIOLOGICAL MARKERS; GENE TRANSFER TECHNIQUES; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICRORNAS; RNA, VIRAL;

EID: 84879312653     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12077     Document Type: Article

References (124)

1. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
2. Amaral PP, Dinger ME, Mercer TR, Mattick JS. The eukaryotic genome as an RNA machine. Science 2008;319:1787-1789.
3. Cullen BR. MicroRNAs as mediators of viral evasion of the immune system. Nat Immunol 2013;14:205-210.
4. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309:1577-1581.
5. Swaminathan S, Murray DD, Kelleher AD. The role of microRNAs in HIV-1 pathogenesis and therapy. AIDS 2012;26:1325-1334.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
7. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004;14:1902-1910.
8. Kim YK, Kim VN. Processing of intronic microRNAs. EMBO J 2007;26:775-783.
9. Tanzer A, Stadler PF. Evolution of microRNAs. Methods Mol Biol 2006;342:335-350.
10. Van Wynsberghe PM, Kai ZS, Massirer KB, Burton VH, Yeo GW, Pasquinelli AE. LIN-28 co-transcriptionally binds primary let-7 to regulate miRNA maturation in Caenorhabditis elegans. Nat Struct Mol Biol 2011;18:302-308.
11. Morlando M, Ballarino M, Gromak N, Pagano F, Bozzoni I, Proudfoot NJ. Primary microRNA transcripts are processed co-transcriptionally. Nat Struct Mol Biol 2008;15:902-909.
12. Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kaminski N, Benos PV. Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS ONE 2009;4:e5279.
13. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006;13:1097-1101.
14. Lee Y, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051-4060.
15. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004;18:3016-3027.
16. Lee Y, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415-419.
17. Gregory RI, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004;432:235-240.
18. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 2004;303:95-98.
19. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363-366.
20. Daniels SM, et al. Characterization of the TRBP domain required for dicer interaction and function in RNA interference. BMC Mol Biol 2009;10:38.
21. Haase AD, et al. TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. EMBO Rep 2005;6:961-967.
22. Lee Y, Hur I, Park SY, Kim YK, Suh MR, Kim VN. The role of PACT in the RNA silencing pathway. EMBO J 2006;25:522-532.
23. Wang HW, et al. Structural insights into RNA processing by the human RISC-loading complex. Nat Struct Mol Biol 2009;16:1148-1153.
24. Trabucchi M, et al. The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature 2009;459:1010-1014.
25. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 2004;15:185-197.
26. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-233.
27. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455:58-63.
28. Walters RW, Bradrick SS, Gromeier M. Poly(A)-binding protein modulates mRNA susceptibility to cap-dependent miRNA-mediated repression. RNA 2010;16:239-250.
29. Fabian MR, et al. Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell 2009;35:868-880.
30. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466:835-840.
31. Beilharz TH, et al. microRNA-mediated messenger RNA deadenylation contributes to translational repression in mammalian cells. PLoS ONE 2009;4:e6783.
32. Sheth U, Parker R. Decapping and decay of messenger RNA occur in cytoplasmic processing bodies. Science 2003;300:805-808.
33. Liu J, Rivas FV, Wohlschlegel J, Yates JR 3rd, Parker R, Hannon GJ. A role for the P-body component GW182 in microRNA function. Nat Cell Biol 2005;7:1261-1266.
34. Eulalio A, Behm-Ansmant I, Schweizer D, Izaurralde E. P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol Cell Biol 2007;27:3970-3981.
35. Omer AD, Janas MM, Novina CD. The chicken or the egg: microRNA-mediated regulation of mRNA translation or mRNA stability. Mol Cell 2009;35:739-740.
36. Weber JA, et al. The MicroRNA Spectrum in 12 Body Fluids. Clin Chem 2010;56:1733-1741.
37. Triboulet R, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007;315:1579-1582.
38. Nathans R, Chu CY, Serquina AK, Lu CC, Cao H, Rana TM. Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell 2009;34:696-709.
39. Houzet L, Yeung ML, de Lame V, Desai D, Smith SM, Jeang KT. MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology 2008;5:118.
40. Ahluwalia JK, et al. Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology 2008;5:117.
41. Sun G, et al. Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res 2012;40:2181-2196.
42. Huang J, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007;13:1241-1247.
43. Witwer KW, Watson AK, Blankson JN, Clements JE. Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients. Retrovirology 2012;9:5.
44. Bignami F, et al. Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. Blood 2012;119:6259-6267.
45. Seddiki N, Swaminathan S, Phetsouphanh C, Kelleher AD. miR-155 is differentially expressed in Treg subsets, which may explain expression level differences of miR-155 in HIV-1 infected patients. Blood 2012;119:6396-6397.
46. Swaminathan S, et al. Differential Regulation of the Let-7 Family of MicroRNAs in CD4+ T Cells Alters IL-10 Expression. J Immunol 2012;118:6238-6246.
47. Seddiki N, et al. The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection. Eur J Immunol 2013;43:510-520.
48. Thiele S, Wittmann J, Jack HM, Pahl A. miR-9 enhances IL-2 production in activated human CD4(+) T cells by repressing Blimp-1. Eur J Immunol 2012;42:2100-2108.
49. Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 2008;26:133-169.
50. Hariharan M, Scaria V, Pillai B, Brahmachari SK. Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun 2005;337:1214-1218.
51. Chiang K, Liu H, Rice AP. miR-132 enhances HIV-1 replication. Virology 2013;438:1-4.
52. Wang X, et al. Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood 2009;113:671-674.
53. Naif HM, et al. CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol 1998;72:830-836.
54. Bishop KN, Holmes RK, Sheehy AM, Malim MH. APOBEC-mediated editing of viral RNA. Science 2004;305:645.
55. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008;451:425-430.
56. Laguette N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011;474:654-657.
57. Cobos Jimenez V, et al. Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons. Sci Rep 2012;2:763.
58. Swaminathan S, Zaunders J, Wilkinson J, Suzuki K, Kelleher AD. Does the presence of anti-HIV miRNAs in monocytes explain their resistance to HIV-1 infection? Blood 2009;113:5029-5030; author reply 30-1.
59. Sung TL, Rice AP. miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1. PLoS Pathog 2009;5:e1000263.
60. Sisk JM, Clements JE, Witwer KW. miRNA Profiles of Monocyte-Lineage Cells Are Consistent with Complicated Roles in HIV-1 Restriction. Viruses 2012;4:1844-1864.
61. Krachmarov CP, Chepenik LG, Barr-Vagell S, Khalili K, Johnson EM. Activation of the JC virus Tat-responsive transcriptional control element by association of the Tat protein of human immunodeficiency virus 1 with cellular protein Purα. Proc Natl Acad Sci 1996;93:14112-14117.
62. Shen CJ, Jia YH, Tian RR, Ding M, Zhang C, Wang JH. Translation of Pur-alpha is targeted by cellular miRNAs to modulate the differentiation-dependent susceptibility of monocytes to HIV-1 infection. FASEB J 2012;26:4755-4764.
63. Coley W, et al. Absence of Dicer in monocytes and its regulation by HIV-1. J Biol Chem 2010;285:31930-31943.
64. Klase Z, et al. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol 2007;8:63.
65. Swaminathan G, Rossi F, Sierra LJ, Gupta A, Navas-Martin S, Martin-Garcia J. A role for microRNA-155 modulation in the anti-HIV-1 effects of Toll-like receptor 3 stimulation in macrophages. PLoS Pathog 2012;8:e1002937.
66. Eletto D, et al. Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J Cell Physiol 2008;216:764-770.
67. Noorbakhsh F, et al. MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival. FASEB J 2010;24:1799-1812.
68. Rom S, et al. CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells. FASEB J 2010;24:2292-2300.
69. Liu Y, et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 2000;6:1380-1387.
70. Yelamanchili SV, Chaudhuri AD, Chen LN, Xiong H, Fox HS. MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. Cell Death Dis 2010;1:e77.
71. Witwer KW, Sisk JM, Gama L, Clements JE. MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J Immunol 2010;184:2369-2376.
72. Pacifici M, et al. Cerebrospinal fluid miRNA profile in HIV-encephalitis. J Cell Physiol 2013;228:1070-1075.
73. Zhou L, et al. A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration. BMC Genomics 2012;13:677.
74. Thomas R, et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009;41:1290-1294.
75. Kulkarni S, et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011;472:495-498.
76. Cullen BR. Is RNA interference involved in intrinsic antiviral immunity in mammals? Nat Immunol 2006;7:563-567.
77. Omoto S, et al. HIV-1 nef suppression by virally encoded microRNA. Retrovirology 2004;1:44.
78. Lin J, Cullen BR. Analysis of the interaction of primate retroviruses with the human RNA interference machinery. J Virol 2007;81:12 218-12 226.
79. Pfeffer S, et al. Identification of microRNAs of the herpesvirus family. Nat Methods 2005;2:269-276.
80. Bennasser Y, Le SY, Benkirane M, Jeang KT. Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 2005;22:607-619.
81. Ouellet DL, et al. Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element. Nucleic Acids Res 2008;36:2353-2365.
82. Klase Z, et al. HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology 2009;6:18.
83. Bennasser Y, Yeung ML, Jeang KT. HIV-1 TAR RNA subverts RNA interference in transfected cells through sequestration of TAR RNA-binding protein, TRBP. J Biol Chem 2006;281:27 674-27 678.
84. Schopman NC, et al. Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs. Nucleic Acids Res 2012;40:414-427.
85. Althaus CF, et al. Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells. Retrovirology 2012;9:27.
86. Kamm RC, Smith AG. Ribonuclease activity in human plasma. Clin Biochem 1972;5:198-200.
87. Arroyo JD, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108:5003-5008.
88. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011;39:7223-7233.
89. Hunter MP, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008;3:e3694.
90. Zernecke A, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009;2:ra81.
91. Kunz C, Schöb H, Stam M, Kooter JM, Meins F. Developmentally regulated silencing and reactivation of tobacco chitinase transgene expression. Plant J 1996;10:437-450.
92. Voinnet O, Baulcombe DC. Systemic signalling in gene silencing. Nature 1997;389:553.
93. Lawrie CH, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-675.
94. Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 2008;105:10513-10518.
95. Chen X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
96. Pegtel DM, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci 2010;107:6328-6333.
97. Haneklaus M, et al. Cutting Edge: miR-223 and EBV miR-BART15 Regulate the NLRP3 Inflammasome and IL-1β Production. J Immunol 2012;189:3795-3799.
98. Li S, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011;124:175-184.
99. Witwer KW, Sarbanes SL, Liu J, Clements JE. A plasma microRNA signature of acute lentiviral infection: biomarkers of central nervous system disease. AIDS 2011;25:2057-2067.
100. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009;139:693-706.
101. Janssen HL, et al. Treatment of HCV Infection by Targeting MicroRNA. N Engl J Med 2013;368:1685-1694.
102. Houzet L, et al. The extent of sequence complementarity correlates with the potency of cellular miRNA-mediated restriction of HIV-1. Nucleic Acids Res 2012;40:11 684-11 696.
103. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003;77:11 531-11 535.
104. Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 2005;33:796-804.
105. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009;457:426-433.
106. Hwang DW, et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011;28:4968-4975.
107. Wolfrum C, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007;25:1149-1157.
108. Hughes J, Yadava P, Mesaros R. Liposomal siRNA delivery. Methods Mol Biol 2010;605:445-459.
109. Trang P, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011;19:1116-1122.
110. Howard KA, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006;14:476-484.
111. Seidl CI, Ryan K. Circular single-stranded synthetic DNA delivery vectors for microRNA. PLoS ONE 2011;6:e16925.
112. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009;61:746-759.
113. Benlahrech A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009;106:19 940-19 945.
114. Hutnick NA, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 2009;15:876-878.
115. O'Brien KL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009;15:873-875.
116. Lahouassa H, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012;13:223-228.
117. Hrecka K, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011;474:658-661.
118. McNamara JO 2nd, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24:1005-1015.
119. Song E, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709-717.
120. Zhang W, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005;11:56-62.
121. Wang Y, Li Z, Han Y, Liang LH, Ji A. Nanoparticle-based delivery system for application of siRNA in vivo. Curr Drug Metab 2010;11:182-196.
122. Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, Cosset FL. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 2002;99:2342-2350.
123. Gantier MP, et al. Rational design of immunostimulatory siRNAs. Mol Ther 2010;18:785-795.
124. Grimm D, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-541.